The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...

The absorption of neffy may be affected in patients with underlying structural or anatomical nasal conditions (eg, nasal polyps, history of nasal surgery). In these patients, epinephrine products ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

During a nasal endoscopy, the health care provider tries to look inside your nose or the opening of the sinus passage to ...

The FDA recently approved the first needle-free epinephrine product (neffy), an alternative to injectable epinephrine (EpiPen ...

Breathing through your nose also releases nitric oxide. Nitric oxide is a vasodilator, which means it helps widen your blood ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...